Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study.

Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, Marcellin P, Cacoub P; CheObs Study Group.

Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1050-7. doi: 10.1097/MEG.0b013e328338d9aa.

PMID:
20351554
[PubMed - indexed for MEDLINE]
2.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, Patel KK, Green J.

Pharmacoeconomics. 2004;22(4):257-65.

PMID:
14974875
[PubMed - indexed for MEDLINE]
3.

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

Keating GM, Curran MP.

Drugs. 2003;63(7):701-30. Review.

PMID:
12656650
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J.

Am J Gastroenterol. 2004 Aug;99(8):1490-6.

PMID:
15307866
[PubMed - indexed for MEDLINE]
5.

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.

Foster GR.

Drugs. 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000. Review.

PMID:
20108989
[PubMed - indexed for MEDLINE]
6.

Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.

Sylvestre DL, Clements BJ.

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):741-7.

PMID:
17700258
[PubMed - indexed for MEDLINE]
7.

Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust study.

Van Vlierberghe H, Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay JP, Van Steenbergen W, Yap P, Nevens F, Denys AM, Brasseur JP.

Acta Gastroenterol Belg. 2010 Jan-Mar;73(1):5-11.

PMID:
20458844
[PubMed - indexed for MEDLINE]
8.

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.

Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.

Gastroenterology. 2010 Jan;138(1):116-22. doi: 10.1053/j.gastro.2009.10.005. Epub 2009 Oct 20.

PMID:
19852964
[PubMed - indexed for MEDLINE]
9.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
[PubMed - indexed for MEDLINE]
10.

High virologic sustained response for former young intravenous drug users with chronic hepatitis C treated by pegylated interferon-alpha plus ribavirin.

Gazdik F, Gazdikova K, Laktis K, Okruhlica L, Fejdiova K, Danis D, Pijak MR, Wsolova L, Kajaba I, Kratky A.

Bratisl Lek Listy. 2009;110(2):77-84.

PMID:
19408838
[PubMed - indexed for MEDLINE]
11.

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group.

Gastroenterology. 2002 Oct;123(4):1061-9.

PMID:
12360468
[PubMed - indexed for MEDLINE]
12.

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote EJ, Gonçales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Albrecht J; Epic Study Group.

Gastroenterology. 2009 May;136(5):1618-28.e2. doi: 10.1053/j.gastro.2009.01.039. Epub 2009 Jan 22.

PMID:
19208349
[PubMed - indexed for MEDLINE]
13.

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B.

Am J Gastroenterol. 2004 Sep;99(9):1733-7.

PMID:
15330911
[PubMed - indexed for MEDLINE]
14.
15.

Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.

Sylvestre DL, Clements BJ, Malibu Y.

Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1057-63.

PMID:
16957511
[PubMed - indexed for MEDLINE]
16.

Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.

Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LG.

Arq Gastroenterol. 2006 Oct-Dec;43(4):275-9.

PMID:
17406754
[PubMed - indexed for MEDLINE]
Free Article
17.

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE; Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group.

Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947.

PMID:
15057741
[PubMed - indexed for MEDLINE]
19.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
20.

Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.

Gallegos-Orozco JF, Fuentes AP, Olivera-Martinez MA, Gutiérrez-Reyes G, Cortina D, Oregel JA, Pérez-Pruna C, Sixtos MS, Cruz-Castellanos S, Soto-Ramírez LE, Rodríguez-Díaz R, Fuentes-Romero L, Gutiérrez-Ruiz MC, Kershenobich D.

Rev Invest Clin. 2003 Mar-Apr;55(2):138-42.

PMID:
12827916
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk